Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

Andrew Blauvelt, Emma Guttman-Yassky, Amy S. Paller, Eric L. Simpson, Michael J. Cork, Jamie Weisman, John Browning, Weily Soong, Xian Sun, Zhen Chen, Matthew P. Kosloski, Mohamed A. Kamal, Dimittri Delevry, Chien Chia Chuang, John T. O’Malley, Ashish Bansal

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Fingerprint

Dive into the research topics of 'Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)'. Together they form a unique fingerprint.

Medicine & Life Sciences